Loading…
Alzamend Neuro, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in ALZN.
▼ -99.9% over 5Y.
today you would have $0.44▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|---|
| Year-end price | $1.83 | $1.82 | $10.44 | $80.10 | $762.75 | $2,565.00 | |
| P/B | 4.0x | 12.0x | 1.3x | — | 1.9x | 4.0x | 80.5x |
| EPS | -$2.63 | -$11.32 | -$132.33 | -$206.01 | -$189.00 | -$94.50 | |
| ROE | -250.71% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AIDX20/20 Biolabs, Inc. | $0.62 | — | 4.7x | — | -331.22% | $7.97M |
| CUPRCuprina Holdings (Cayman) LTD | $3.01 | — | 2.0x | — | -1569.06% | $8.07M |
| CNSPCNS Pharmaceuticals, Inc. | $5.52 | — | 0.4x | — | -106.62% | $8.07M |
| ICCMIceCure Medical Ltd. | $2.30 |
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Company description provided by Yahoo Finance.
| -1196.43% |
| -113.78% |
| — |
| -488.53% |
| -92.59% |
| -250.71% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.7x |
| — |
| -228.31% |
| $7.88M |
| TRIBTrinity Biotech PLC | $9.68 | — | — | — | — | $7.87M |
| AIMAIM ImmunoTech Inc. | $0.26 | — | 1.0x | — | -2382.30% | $7.87M |